Oxford Biomedica

Jason Slingsby, Ph.D., Chief Business Officer
Oxford, UK
Oxford Biomedica (OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica has built a sector leading lentiviral vector delivery platform (LentiVector®), which we leverage to develop in vivo and ex vivo products both in-house and with partners. OXB has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases, and respiratory disease. OXB has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for the manufacture of the adenovirus based COVID-19 vaccine candidate, AZD1222.

By using this website you agree to accept our Privacy Policy and Terms & Conditions